NEJM publishes data from phase 3 inTandem3 study of Sotagliflozin for type 1 diabetes
Lexicon Pharma announced the New England Journal of Medicine published the results of the Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for treatment of patients with type 1 diabetes on any background insulin therapy. September 13, 2017